Kexing
Biopharm

KEXING BIOPHARM CO., LTD.

Tel:0086-531-55763601/02/03　　E-mail：sales@kexing.com
Website:www.kexingbiopharm.com

Precise Products
Predictable Effects
Health Protection

Kexing
Biopharm

Kexing
Biopharm

A leader in China recombinant protein therapeutics industry

Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein drugs and microecological preparations. Focusing on antiviral therapy and the treatment of tumor,autoimmune, kidney disease, digestive, endocrine, degenerative diseases and other fields, it is dedicated to building globally leading industrial platforms for new protein, new antibody, nucleic acid and other drugs. Adhering to the platform-driven development model of "innovation+ internationalization", it also explores the extensive application of biotechnology in the big health sector. It is committed to becoming a leader in high-quality biological drugs and serving global patients.

At present, our main products include "Human Erythropoietin (EPOSINO)", "Human Interferon α 1b (SINOGEN)", "Human Granulocyte Stimulating Factor (WHITE-C)" ,"Combined Clostridium Butyricum and Bifidobacterium live (CLOBICO) ","Kehuang capsule ", "Entecavir (SINGENSU) "," Paclitaxel for Injection (Albumin-Bound)(Apexelsin), " Infliximab (Reminton) "," Bevacizumab (Arketin)","Adalimumab (Ahrasin) ", "Liraglutide (Exinkira) ", " Trastuzumab (Acurvigta) ", " Neratinib Maleate (ALCOMHER) ", " Lenalidomide ", " Sevelamer Carbonate (Exlimcon) ", "Eribulin Mesylate", " Sorafenib Tosylate (Airkefay) ", "Palbociclib (Aubervis) ", " Olaparib " etc.

In recent years, we have achieved continued and rapid growth in its business, becoming a leader in the recombinant protein therapeutics industry. Our core products, remained at the forefront of similar varieties in China, have been adopted by over 20000 sales terminals, including over 7000 hospitals in the provinces, municipalities and regions across China, and accessed into and sold in nearly 70 countries, including European Union, Brazil, Philippines and Indonesia.

With over two decades of accumulation in pharmaceutical R&D and industrialization, we have established a complete system of pharmaceutical R&D innovation, covering pharmaceutical innovation capabilities from pharmaceutical discovery, pharmaceutical research, preclinical research and clinical research to industrialized production.

Depending on prokaryotic cell technology system,eukaryotic cell technology system and nucleic acid and virus technology system, we have built 5 world-leading technology platforms, including KX-FUSION protein technology platform, KX-body antibody technology platform, K'Exosome delivery technology platform, Vector vaccine technology platform, Microecological agent R&D and industrialization platform.

At present, we have obtained 63 patents, more than 10 biopharmaceutical projects are being studied.

Following the mission of "Precise Products, Predictable Effects, Health Protection", we are devoted to providing patients with biotechnology, becoming the leader in high quality biologics.

Kexing
Biopharm

WHITE-C

Human Granulocyte Colony-stimulating Factor Injection

Kexing Biopharm

A clinical first-line drug for prevention and treatment of neutropenia after tumor chemoradiotherapy

Indications

- Neutropenia due to cancer chemotherapy and other reasons;
- Neutropenia due to chemotherapy for acute leukemia.

Precise Products Predictable Effects Health Protection

WHITE-C

Since its introduction into the market in 2001, WHITE-C has been clinically applied for more than 20 years, with a wide range of evidence-based applications, topping the list of domestic similar products in terms of export volume. As strict in-house control quality standards are followed, WHITE-C is not only in line with Chinese Pharmacopoeia, but also European Pharmacopoeia.

Advantages

- Early introduction into the market, clinically applied for more than 20 years, a relatively wide range of evidence-based applications;
- Registered into and sold in 22 countries and regions.

Commonly used departments

- Oncology
- Hematology
- Radiotherapy
- Gynecology
- Breast
- Thoracic medicine and other departments related to tumor chemoradiotherapy

Strength

- 75ug/0.5ml/vial(vial)
- 150ug/0.5ml/vial(vial)
- 300ug/ml/vial(vial)
- 75ug/0.5ml/syringe (pre-lled syringe)
- 150ug/0.5ml/syringe (pre-lled syringe)
- 150ug/ml/syringe (pre-lled syringe)

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

APEXELSIN

Paclitaxel For Injection
(Albumin Bound)

Kexing
Biopharm

Blockbuster drugs in tumor chemotherapy, Approved for listing in China and the European Union

Indications

- Albumin-bound paclitaxel monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated;
- Albumin-bound paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas;
- Albumin-bound paclitaxel in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

Precise Products Predictable Effects Health Protection

APEXELSIN

Albumin-bound paclitaxel takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility, featured by "Three Highs and One Low", i.e. high dose, high distribution in tumor tissue, high efficacy, and low toxicity. Albumin-bound paclitaxel is recommended by the NCCN and CSCO guidelines for the treatment of breast cancer. It is the only product in China that is applied simultaneously in China, the United States, and the European Union, and has obtained the Chinese marketing license and the EU approval for marketing as well.

Advantages

- It is a high-end complex drug product enhanced by nanotechnology;
- The efficacy and safety of albumin-bound paclitaxel are superior to those of solvent-based paclitaxel and docetaxel, and it is the optimal choice for breast cancer treatment;
- Apexelsin has obtained the Chinese marketing license and the EU approval for marketing as well.

Commonly used departments

- Oncology Department
- Gynaecology
- Respiratory Medicine
- Pancreatology Department
- Hepatobiliary Surgery

Strength

- 100 mg/vial

Kexing
Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

ARKETIN

Bevacizumab Injection

Kexing Biopharm

Fully humanized monoclonal antibody biosimilar as a broad-spectrum antitumor drug

Indications

- Metastatic colorectal cancer;
- Advanced, metastatic, or recurrent non-small cell lung cancer;
- Recurrent glioblastoma;
- Epithelial ovarian cancer, fallopiantube cancer, or primary peritoneal cancer;
- Cervical cancer.

Precise Products Predictable Effects Health Protection

ARKETIN

ARKETIN

Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb), specifically binds to VEGF to prevent VEGF from binding to its receptor, thereby reducing neovascularization, inducing degeneration of existing blood vessels and inhibiting tumor growth. As a broad-spectrum anti-tumor agent, bevacizumab is a standard regimen recommended in treatment guidelines for various malig nancies worldwide. Since entering the market, its efficacy and safety have been widely demonstrated in clinical practice.

Advantages

- It is included in the National Reimbursement Drug List;
- As a broad-spectrum anti-tumor agent, it is recommended as a standard regimen in treatment guidelines for various malignancies worldwide;
- It is subject to several rigorous and comprehensive head-to-head studies with the originator product (Avastin by Roche);
- It is suitable for the extended application for all 8 indications of the originator product in China.

Commonly used departments

- Oncology
- Thoracic Surgery
- Gynecology
- Respiratory Medicine
- Anorectal Medicine

Strength

- 100 mg/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

ACURVIGTA
Trastuzumab Injection

Kexing Biopharm

Drug for full-course treatment of HER2+ breast cancer

Indications

- HER2-positive metastatic breast cancer;
- Early-stage breast cancer and metastatic gastric cancer.

Precise Products Predictable Effects Health Protection

ACURVIGTA

Trastuzumab can bind to human epidermal growth factor receptor 2 (HER2) receptors with high specificity, prevent EGF from rebinding to HER2, and then delay the growth of tumor cells. It is widely used in the treatment for metastatic breast cancer, early-stage breast cancer and metastatic gastric cancer. The brand-name product of trastuzumab was launched in the United States in 1998. With its excellent clinical profiles, trastuzumab with expanded indications has become a drug used in the full treatment course of HER2+ breast cancer with great significance in this field.

Advantages

- Trastuzumab is the first innovative drug targeting HER2+ breast cancer worldwide and the cornerstone of HER2+ breast cancer treatment;
- A series of immunogenicity, pharmaceutical, non-clinical and clinical comparative studies have shown that it is highly consistent with the brand-name product of trastuzumab, with equivalent clinical efficacy, similar safety, covering all indications approved for the brand-name product in China;
- 150 mg/vial, without preservatives; use immediately after preparation with any unused portion discarded to ensure the safe medication for patients and standardized management of drug use and benefit both patients and medical staff.

Commonly used departments

- Oncology
- Breast Surgery
- Gastrointestinal Surgery

Strength

- 150 mg/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

LENALIDOMIDE CAPSULES

Kexing Biopharm

First-line drug recommended by guidelines for the treatment of multiple myeloma and myelodysplastic syndrome



Indications

- Multiple myeloma in previously untreated adult patients who are not suitable for transplantation (in combination with dexamethasone).
- Multiple myeloma in adult patients who have received at least one therapy (in combination with dexamethasone).
- Follicular lymphoma (grade 1-3A) in previously treated adult patients (in combination with rituximab).

Precise Products Predictable Effects Health Protection

LENALIDOMIDE

Lenalidomide is a new generation of immunomodulatory anti-tumor drug with a wide range of mechanisms of action including anti-tumor angiogenesis and improving immune function and bone marrow microenvironment. It is clinically used in treatment of multiple myeloma, lymphoma, myelodysplastic syndrome, acute myeloid leukemia and other diseases, and is currently the first-line drug recommended by the guidelines for the treatment of multiple myeloma and myelodysplastic syndrome.



Advantages

- High-quality generic drugs, with all specifications and bioequivalence equivalent to those of the brand-name drug;
- It is the first oral drug for multiple myeloma. Patients do not need to be hospitalized when taking lenalidomide, and can take it on their own according to medical advice;
- It is approved for use in combination with rituximab for the treatment of lymphoma indications, providing a justification for clinical prescription and bringing a more economical, effective and safer treatment option to patients with lymphoma.

Commonly used departments

- Hematology
- Oncology

Strength

- 5mg
- 10mg
- 25mg

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

ALCOMHER
Neratinib Maleate Tablets

Kexing Biopharm

New drug for extended adjuvant therapy of HER2+ breast cancer worldwide

Indications

For extended adjuvant therapy after adjuvant trastuzumab-based therapy in patients with early-stage HER2-positive breast cancer.

Precise Products Predictable Effects Health Protection

ALCOMHER

ALCOMHER

Neratinib Maleate Tablets is an oral irreversible small molecule pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI) indicated for the extended adjuvant treatment of adult patients with early-stage HER2+ breast cancer after adjuvant trastuzumab-based therapy and the treatment of adult patients with metastatic advanced HER2+ breast cancer who have received two or more treatment regimens, recommended by many authoritative guidelines worldwide.

Advantages

- Oral TKI used for extended adjuvant therapy of HER2+ breast cancer worldwide, with a wide range of targets;
- Recommended by authoritative guidelines worldwide including 2020 NCCN Guidelines for Breast Cancer, ASCO, ESMO, Guidelines of China Anti-Cancer Association (CACA) for Breast Cancer, and Guidelines of Chinese Society Of Clinical Oncology (CSCO) for Breast Cancer as the drug for extended adjuvant therapy;
- Sequential use of neratinib can significantly reduce the risk of recurrence in patients with early-stage HER2+ breast cancer after adjuvant trastuzumab-based therapy.

Commonly used departments

- Oncology
- Breast Surgery

Strength

- 40mg,180 tablets/bottle

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

ERIBULIN
Mesylate Injection

Kexing Biopharm

The synthesis is extremely difficult and is known as the "mount everest" in the field of chemical and pharmaceutical synthesis



Indications

- For the treatment of patients with metastatic breast cancer who have received at least two previous treatment regimens, including anthracycline and taxane.
- For the treatment of patients with unresectable or metastatic liposarcoma who have been treated with anthracycline-containing drugs.

Precise Products Predictable Effects Health Protection

ERIBULIN

Eribulin Mesylate injection is indicated for patients with locally advanced or metastatic breast cancer who have previously received at least two chemotherapy regimens. As a new choice for yew and anthracycline resistance, it enables drug-resistant patients to achieve overall survival benefits, and is the preferred drug for advanced breast cancer.
As the most difficult compound to synthesize in the synthetic world, the compound contains 19 chiral centers, theoretically 524,287 aberrations, and more than 65 synthetic steps, which is extremely difficult to synthesize, and is known as the "Everest" in the field of chemical and drug synthesis, with few competitors and good market prospects.

Advantages

- A rare product in China that can be declared simultaneously in China, the United States and the European Union;
- The synthesis is extremely difficult and is known as the "Mount Everest" in the field of chemical and pharmaceutical synthesis;
- With a unique anti-tumor mechanism, a single drug can extend the survival time of advanced breast cancer patients and significantly improve the quality of life of patients.

Commonly used departments

- Oncology department
- Gynecology

Strength

- 1mg/2mL

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

AIRKEFAY

Sorafenib Tosylate Tablets

Kexing Biopharm

The world's first approved multi target anti-cancer drug

Indications

- Hepatocellular Carcinoma

Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

- Differentiated Thyroid Carcinoma

Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic.progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Precise Products Predictable Effects Health Protection

AIRKEFAY

Sorafenib is an oral multi-target receptor tyrosine kinase inhibitor, which can block tumor cell proliferation, inhibit angiogenesis, and induce tumor cell apoptosis. It has good anti-tumor activity, and is mainly used in the treatment of advanced renal cell carcinoma. At present, it is also the first molecular targeted drug with good efficacy in the treatment of liver cancer.

Advantages

- An oral multi-target, multi-kinase inhibitor;
- Sorafenib exerts dual effects of anti-angiogenesis and anti-tumor cell proliferation at the same time;
- Sorafenib Tosylate Tablets have been approved for marketing by the NMPA in 2021 and by the FDA in 2022.

Commonly used departments

- Oncology department
- Department of hepatology
- Thyroid surgery
- Respiratory medicine
- Nephrology department

Strength

- 200mg/tablet

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

AUBERVIS
Palbociclib Capsules

Kexing Biopharm

The world's first CDK4/6 targeted inhibitor approved for HR+/ HER2-type locally advanced or metastatic breast cancer

Indications

- Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:
  - in combination with an aromatase inhibitor;
  - in combination with fulvestrant in women who have received prior endocrine therapy .
- In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

Precise Products Predictable Effects Health Protection

AUBERVIS

Breast cancer is the most common malignant tumor in women, of which HR+/HER2- breast cancer accounts for more than 60%. Palbociclib is the world's first approved CDK4/6 inhibitor, and its emergence opens a new era of endocrine therapy for HR+/HER2- advanced breast cancer. Compared with previous endocrine therapy alone, the combination of Palbociclib significantly extends the survival time of patients.

Advantages

- Palbociclib is an oral small molecule cyclin-dependent kinase (CDK4/6) inhibitor and is the first CDK4/6 inhibitor approved globally for HR+/ HER2-locally advanced or metastatic breast cancer;
- Complete drug specifications, in line with China and the US declaration standards, has been approved in Chinese , and has been submitted NDA in the US.

Commonly used departments

- Oncology department
- Gynecology

Strength

- 75mg/capsule
- 100mg/capsule
- 125mg/capsule

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

OLAPARIB TABLETS

Kexing Biopharm

The first PARP inhibitor has the potential to be a broad-spectrum antitumor drug

Indications

- This product is indicated for maintenance treatment in newly treated adult patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer carrying germ line or somatic BRCA mutations (gBRCAm or sBRCAm) after first-line platinum-containing chemotherapy has achieved complete or partial response;
- Maintenance therapy in adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after achieving complete or partial response to platinum-containing chemotherapy.

Precise Products Predictable Effects Health Protection

OLAPARIB

Olaparib Tablets, as a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor,by inhibiting the activity of PARP enzyme, the DNA repair ability of tumor cells is hindered, which leads to the death of tumor cells.Olaparib Tablets is initially indicated for BRCA-mutated advanced ovarian cancer, and subsequently expanded to ovarian cancer, breast cancer, pancreatic cancer, prostate cancer and other malignancies. It is a first-line therapeutic agent for breast cancer and a first-line maintenance therapy for ovarian cancer recommended by the NCCN clinical guidelines.

Advantages

- The first PARP inhibitor has the potential to be a broad-spectrum antitumor drug;
- Olaparib tablets are produced by hot melt extrusion technology, which is a high-end preparation.

Commonly used departments

- Oncology department
- Gynecology

Strength

- 100mg/tablet
- 150mg/tablet

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

CLOBICO

Combined Clostridium Butyricum and Bifidobacterium Capsule, Live

Kexing Biopharm

An exclusive probiotic product available to the old, the young, as well as pregnant and lying-in women

Indications

• Acute and chronic diarrhea caused by acute non-specic infection, intestinal ora imbalance caused by antibiotics, chronic liver disease and other reasons, and related acute and chronic diarrhea and dyspepsia.

Precise Products Predictable Effects Health Protection

CLOBICO

Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO) is a combination of clostridium butyricunm and bifidobacterium infantis. Both bacterial strains are dominant in autochthonous intestinal flora and can synergistically promote the growth of each other. With proven immunoregulatory effect and a wide range of clinical applications and evidence-based support, it is a probiotic that is explicitly approved for use by the old, the young, as well as pregnant women before and after delivery, in the package insert.



Advantages

- The first-in-class drug of biopharmaceuticals, exclusive formula of autochthonous flora, a combination of autochthonous flora producing butyric acid and lactic acid;
- A widely used probiotic product available to the old, the young as well as pregnant and lying-in women, filling the gap in clinical medication.

Commonly used departments

- Pediatric Gastroenterology
- Pediatric Pneumology
- Gastroenterology
- Neonatology
- Infectious Diseases
- Obstetrics And Gynecology
- Geriatrics And Oncology

Strength

- 500 mg/sachet
- 420 mg/capsule

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

REMINTON
Infliximab for Injection

Kexing Biopharm

The first infliximab biosimilar marketed in China

Indications

- Crohn's disease in adults and children over 6 years of age;
- Stulizing Crohn's disease;
- Ulcerative colitis in adults;
- Ankylosing spondylitis;
- Rheumatoid arthritis, and psoriasis.

Precise Products Predictable Effects Health Protection

REMINTON

Reminton, a recombinant anti-TNF-a monoclonal antibody was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Reminton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.



Advantages

- It is the first infliximab biosimilar marketed in China;
- Its efficacy and safety are equivalent to those of the originator product (Remicade® by Johnson & Johnson and Merck).

Commonly used departments

- Rheumatology and Immunology
- Gastroenterology
- Dermatology
- Anorectal Surgery
- Pediatrics

Strength

- 100 mg/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

AHRASIN

Adalimumab
Solution for Injection

Kexing Biopharm

As a blockbuster drug in the field of autoimmune diseases, Adalimumab has topped the list of the world's best-selling drugs for many consecutive years



Indications

- Rheumatoid Arthritis
- Ankylosing spondylitis
- Psoriasis
- Crohn's disease
- Uveitis
- Plaque psoriasis in children
- Crohn's disease in children
- Polyarticular juvenile idiopathic arthritis

Precise Products Predictable Effects Health Protection

AHRASIN

AHRASIN

Adalimumab is a fully human anti-tumor necrosis factor-a (TNF-a) monoclonal antibody, Excessive inflammation in a variety of immune-mediated diseases in humans are associated with TNF-a.

It can be selectively related to TNF-a Molecule binding prevents it from attaching to healthy cells, thereby reducing excessive TNF-a Damage caused. Based on this principle, Adalimumab can be used to treat a variety of immune mediated diseases.

Advantages

- **Fully human anti-tumor necrosis factor-a (TNF-a) monoclonal antibody,** a biosimilar drug of HUMIRA ;
- Launched in 2019, the second domestic adalimumab biosimilar drugs in China;
- The prescription has independent intellectual property rights and has been authorized by Chinese and Russian patents;
- Domestic adalimumab sales of the highest.

Commonly used departments

- Rheumatology and immunology Department
- Gastroenterology
- Dermatology
- Ophthalmology

Strength

- 0.8ml: 40mg

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

EPOSINO

Human Erythropoietin Injection

Kexing Biopharm

A clinical first-line drug and an industry-leading product for the treatment of anemia in many fields



Indications

- Anemia caused by renal dysfunction, including dialysis and non-dialysis patients;
- Perioperative erythrocyte mobilization;
- Anemia caused by chemotherapy for non-myeloid malignancies.

Precise Products Predictable Effects Health Protection

EPOSINO

EPOSINO

EPOSINO is the first batch of human erythropoietin approved for R&D in China and obtained the New Drug Certificate and NMPA's official approval number. It is complete in dosage forms and strengths and firstly administrated by pre-filled syringes for more convenient clinical drug selection. As an industry-leading product, it has been accessed into and sold in more than 30 countries, including Brazil, Philippines and Indonesia.

Advantages

- Patented formula free of human albumin;
- EPOSINO ranks second in Chinese erythropoietin;
- Registered and sold in more than 30 countries and regions, topping the list of similar products in terms of export volume.

Commonly used departments

- Kidney Diseases (Renal Anemial)
- Oncology (Tumor-associated Anemial)
- Surgery (Perioperative Anemial)
- Hematology

Strength

- 2000IU/1ml/ vial (vial)
- 2000IU/0.5ml/syringe (pre-lled syringe)
- 3000IU/1ml/syringe (pre-lled syringe)
- 4000IU/0.5ml/syringe (pre-lled syringe)
- 6000IU/0.5ml/syringe (pre-lled syringe)
- 10000IU/0.5ml/syringe (pre-lled syringe)
- 2000IU/1ml/syringe (pre-lled syringe)
- 3000IU/1ml/vial (vial)
- 4000IU/1ml/syringe (pre-lled syringe)
- 6000IU/1ml/syringe (pre-lled syringe)
- 10000IU/1ml/syringe (pre-lled syringe)
- 36000IU/1ml/syringe (pre-lled syringe)

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

EXLIMCON
Sevelamer
Carbonate Tablets

Kexing
Biopharm

Guidelines recommend first-line drugs for the clinical treatment of hyperphosphatemia in adults with chronic kidney disease (CKD)

Indications

Sevelamer carbonate tablets are a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.

Precise Products Predictable Effects Health Protection

EXLIMCON

EXLIMCON

In recent years, the incidence and hospitalization rate of chronic kidney disease (CKD), especially end-stage renal disease, have increased significantly, seriously threatening human health. Sevelamer carbonate is a new generation of non-absorbable phosphate binding crosslinked polymers, which can reduce the concentration of phosphate in serum by binding to phosphate in digestive tract and reducing its absorption. It is clinically used to control hyperphosphatemia in adult patients with chronic kidney disease (CKD) undergoing dialysis treatment and is the first-line drug recommended by clinical treatment guidelines.

Advantages

- It has a unique mechanism of action, which can effectively reduce blood phosphorus and achieve the purpose of early intervention;
- As a non-calcium-phosphorus binding agent, Sevelamer can effectively avoid the increase of calcium load, thereby delaying the progression of vascular calcification and renal failure;
- Sevelamer does not contain other metal components and is not absorbed into the blood, avoiding the risk of accumulation.

Commonly used departments

- Nephrology department
- Hemodialysis room

Strength

- 800mg/Film-coated Tablets

Kexing
Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

SINOGEN

Human Interferon α1b for Injection

Kexing Biopharm

A classic broad-spectrum antiviral drug and an industry-leading product

Indications

- Viral diseases and some malignant tumors;
- Chronic hepatitis B, hepatitis C and hairy cell leukemia;
- Viral diseases such as herpes zoster, condyloma acuminata, epidemic hemorrhagic fever and respiratory syncytial virus pneumonia in children;
- Malignant tumors such as chronic myelogenous leukemia, melanoma and lymphoma.

Precise Products Predictable Effects Health Protection

SINOGEN

SINOGEN

The first α1b interferon in the world using Chinese gene for cloning and expression, which makes its clinical use consistent with the natural antiviral status of Chinese population. It has high purity, good stability, stronger antiviral activity and immune regulation ability, and lower neutralization antibody production rate and drug antigenicity.

The emergence of SINOGEN has broken the monopoly situation of interferon products from Europe and America in China. The birth of SINOGEN has brought about a brand-new biotechnological revolution, which is a milestone of epoch-making significance to Kexing or even the entire R&D field of biopharma-ceutical in China.

Advantages

- The first genetically engineered new drug in China;
- Broad-spectrum antiviral, anti-tumor, immunity-enhancing effect;
- Complete in strengths (6 product strengths), extensive indications;
- Interferon subtypes with pediatric indications labeled.

Commonly used departments

- Pediatric
- Respiratory Medicine
- Hepatology
- Infectious Disease
- Dermatology
- Gynecology
- Hematology
- Oncology

Strength

- 10ug/vial
- 20ug/vial
- 30ug/vial
- 40ug/vial
- 50ug/vial
- 60ug/vial

Kexing Biopharm

KEXING BIOPHARM CO., LTD.

Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

KEHUANG CAPSULE

Kexing Biopharm

National patent-protected brand and an optimal medicine that specializes in curing heat, toxin, swelling and pain

Indications

- Heat clearing and detoxication;
- Stasis resolving and bind dissipating;
- Applicable to the pattern of retained damp-heat and pathogenic toxin and pattern of blood stasis obstructing the collaterals, such as distending pain of lateral thorax, hypochondriac lump, bitter sticky mouth, poor appetite and abdominal distension, yellow face and eyes, short and reddish urine, dark redness or ecchymosis and petechia on tongue, yellow greasy tongue coating, and slippery, string-like or rough pulse; as well as acute and chronic hepatitis.

Precise Products Predictable Effects Health Protection

KEHUANG

KEHUANG

Kehuang Capsule originated from the Shaolin Temple in Quanzhou of Fujian Province in 1867 (during the reign of Emperor Tongzhi in Qing Dynasty), and is mainly composed of precious medicinal materials such as She Xiang (Moschus), Niu Huang (Calculus Bovis), San Qi (Panax Notoginseng) and She Dan Zhi (Fel Serpentis). Back in 1927, pestilences, hepatitis and dyspepsia particularly, were raging in Quanzhou, and people found that Kehuang Capsule can achieve positive efficacy in curing these diseases. Hence Kehuang Capsule got its name. After these findings, Kehuang Capsule became popular among folks in the inland of southern Fujian and earned the trust of the masses.

Afterwards, Kehuang Capsule was introduced and inherited in Taiwan and Hong Kong, and was manufactured by Taiwan Oriental Traditional Chinese Medicine Company and Hong Kong Oriental Traditional Chinese Medicine Company. Later on, Kehuang Capsule became influential and popular in Southeast Asia, Europe, America, and Japan.

In 1989, our company started to cooperate with Taiwan Oriental Traditional Chinese Medicine Company to develop this brand. On one hand, we continued using the traditional fermentation technique; on the other hand, we conducted all related developmental work such as establishment of process specification, researches on pharmacology & toxicology and clinical studies. In September 1994, Kehuang Capsule received New Drug Certificate and was permit- ted to be manufactured. Since then, Kehuang Capsule has begun to revive in mainland China.

Strength

- 0.4g/capsule

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

SINGENSU
Entecavir Tablets

Kexing Biopharm

An anti-hepatitis B drug with the lowest drug resistance rate

Indications

• Chronic hepatitis B in adults with active viral replication, persistently elevated serum alanine aminotransferase (ALT), or active disease by liver histology.

Precise Products Predictable Effects Health Protection

SINGENSU

SINGENSU

SINGENSU, a guanine nucleotide analog, inhibits the reverse transcriptase of hepatitis B virus. It is currently the anti-hepatitis B drug with the lowest drug resistance rate as well as favorable safety and tolerability，and also recommended as the first-line antiviral drug in many authoritative guidelines for the diagnosis and treatment of hepatitis B worldwide.

Advantages

- It has passed the consistency evaluation of generic drugs;
- It has favorable safety and tolerability;
- It is recommended as the rst-line antiviral drug in many authoritative guidelines for the diagnosis and treatment of hepatitis B worldwide;
- It is the Top 1 product on the list of systemic antiviral drugs in public medical institutions in China.

Commonly used departments

- Hepatology

Strength

- 0.5 mg/tablet

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com

EXINKIRA
Liraglutide Injection

Kexing Biopharm

A blockbuster drug in the field of diabetes, with significant hypoglycemic effect

Indications

Blood glucose control in adult patients with type 2 diabetes.

Precise Products Predictable Effects Health Protection

EXINKIRA

EXINKIRA

Liraglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist, which promotes insulin secretion based on blood glucose level, protects islet ß cells, delays gastric emptying and reduces appetite. As an emerging new drug for diabetes treatment in recent years, it can effectively reduce blood glucose level, with low risk of hypoglycemia, which is indicated for blood glucose control in adult patients with type 2 diabetes.

Advantages

- The second liraglutide injection applied for marketing in China;
- Manufacturer: a leading manufacturer in the insulin field of China;
- Convenient medication: Only need to take medication once a day, without limiting the duration of administration;
- It not only has good hypoglycemic effect, but also has significant advantages such as weight loss, blood pressure reduction, and improving blood lipid profile.

Commonly used departments

- Endocrinology

Strength

- 3 mL: 18 mg (pre-filled)

Kexing Biopharm

KEXING BIOPHARM CO., LTD.
Tel:0086-531-55763601/02/03 E-mail:sales@kexing.com Website:www.kexingbiopharm.com